Pharmaceuticals showing strength this earnings season
It's been a banner quarter for large-cap pharmaceutical companies. We've had earnings beats and guidance upgrades from GlaxoSmithKline, Biogen, Bristol-Myers Squibb, Merck, Celgene, and Procter & Gamble. More earnings beats may be coming, with Amgen reporting today after market and Amarin tomorrow. In my opinion, the whole sector is set to surge, and the leveraged Direxion Biotech Bull ETF could be a very strong play this quarter if you can find a good entry point.
